Latest Pharmaceutical Regulatory News News

Page 1 of 1

Health Canada Extends SCENESSE® Review, Delaying EPP Treatment Approval

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

Ada Torres

16 Oct 2025

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026